Nine new hires get rights to buy 128,250 Kura shares, phased in over four years.
Kura Oncology (KURA) granted stock options to nine new employees to purchase 128,250 common shares as employment inducements. The options have an exercise price of $10.65 per share, matching the closing price on October 1, 2026, and will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months, contingent on continued service. These grants were made under the company's 2023 Inducement Option Plan and approved under Nasdaq Listing Rule 5635(c)(4).
A tax-related sale leaves Kura Oncology (KURA) legal chief with 187,002 shares.
Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, sold 8,442 common shares at $10.4973 each on September 28, 2026, as a "sell-to-cover" transaction for taxes. This sale was related to the vesting of 1/6th of her performance-based restricted stock units (PSUs), which occurred after a development milestone was met on September 27, 2026. Following the sale, she directly holds 187,002 shares of Kura Oncology.
A tax-related sale followed stock vesting: Kura Oncology (KURA) executive sold 4,607 shares.
Kura Oncology's SVP, Finance & Accounting, Thomas James Doyle, sold 4,607 shares of common stock on September 28, 2026, for $10.4972 per share. This transaction was a "sell-to-cover" for taxes due to the vesting of performance-based restricted stock units. Following the sale, Doyle directly holds 142,428 shares and indirectly holds 500 shares through his spouse's 401(k).
After three earlier sales, a Kura Oncology (KURA) officer proposes another share sale
Kura Oncology officer Brian Powl has proposed selling 15,430 common shares, valued at $163,712.30, with an approximate sale date of September 29, 2026. This proposed sale follows three prior sales by Powl in the last three months, totaling 21,365 shares. The filing details the transaction and previous sales, providing context on insider trading activities and relevant SEC rules like Rule 144 and 10b5-1 Sales.
Form 4 Kura Oncology Inc For: 29 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Kura Oncology Inc. specifically for September 29. It includes the stock symbol KURA and briefly mentions its performance. The content is very short and mainly serves as a placeholder for the SEC filing information.
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR
Kura Oncology, Inc. (HAN:KUR) reported its latest quarterly earnings, surpassing analyst estimates for both EPS and revenue. The company posted a diluted EPS of -0.67 EUR, beating the -0.77 EUR estimate by 12.23%, and revenue reached 18.28M EUR against an 17.65M EUR estimate. Analysts anticipate earnings per share of -0.72 EUR and revenue of 20.98M EUR for the upcoming quarter.
Kura Oncology SVP sells $48,360 of stock
Thomas Doyle, SVP of Finance & Accounting at Kura Oncology (NASDAQ:KURA), sold 4,607 shares of stock for approximately $48,360 to cover tax withholding obligations from vested restricted stock units. This transaction comes amidst Kura Oncology reporting strong Q2 2026 results, exceeding analyst expectations for both adjusted loss and revenue, largely due to KOMZIFTI sales. The company also saw significant insider stock purchases by CEO Troy Edward Wilson and received a "Market Outperform" rating with a $24.00 price target from Citizens.
Kura Oncology COO Kathleen Ford sells $111,930 in company stock
Kura Oncology's COO, Kathleen Ford, sold company stock totaling $111,930 across two separate transactions on September 28 and 29, 2026. These sales were primarily conducted to cover taxes related to the vesting of performance-based restricted stock units. Despite the recent sales by the COO, Kura Oncology recently reported strong Q2 2026 results, exceeding analyst expectations, and its President and CEO also made a significant insider purchase of 100,000 shares.
Kura Oncology CMO Mollie Leoni reports $440,236 stock sales
Mollie Leoni, Chief Medical Officer at Kura Oncology (NASDAQ:KURA), reported selling $440,236 worth of company stock in late September 2026 across two transactions. These sales, conducted at prices around $10.81 per share, were partly "sell-to-cover" for taxes related to vested performance-based restricted stock units and partly executed under a pre-established Rule 10b5-1 trading plan. Despite a recent 2% stock dip, Kura Oncology's stock had gained 33% over the prior six months, and the company recently surpassed Q2 2026 financial expectations and saw insider stock purchases by its CEO.
One sale covered taxes; two followed a trading plan. Kura Oncology (KURA) executive sold 32,450 shares.
Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold a total of 32,450 shares of common stock across three transactions on September 28 and 29, 2026. One sale of 9,020 shares was a "sell-to-cover" for taxes related to RSU vesting, while the other two sales totaling 23,430 shares were executed under a Rule 10b5-1 trading plan adopted in May 2026. After these transactions, Powl directly holds 136,819 shares of Kura Oncology common stock.
Return on equity % of Kura Oncology, Inc. – HAN:KUR
The article provides a financial overview of Kura Oncology, Inc. (HAN:KUR), specifically focusing on its Return on Equity (ROE) percentage. It lists the company on the Hannover Stock Exchange and mentions that the market is currently closed with no trades. The content primarily serves as a placeholder for financial data and navigation within the TradingView platform.
Kura Oncology, Inc. Revenue Breakdown – HAN:KUR
Kura Oncology, Inc. (HAN:KUR) generated €57.46 million in revenue last year, primarily from its Precision Medicines segment. The United States was the largest geographical contributor to this revenue, accounting for the entire reported amount. This marks an increase from the previous year's revenue of €52.05 million.
After selling 12,448 shares, a Kura Oncology (KURA) officer proposes selling 28,802 more.
Kura Oncology officer Mollie Vanessa Leoni has filed a notice proposing to sell 28,802 common shares of KURA, valued at approximately $305,589.22, with an approximate sale date of September 29, 2026. This proposed sale follows her previous sale of 12,448 common shares totaling $130,670.01 within the preceding three months. The shares for the proposed sale originate from performance stock units.
An August sale of 31,487 stock units precedes another proposed sale by Kura Oncology (KURA) officer Teresa Bair.
Kura Oncology officer Teresa Bair has proposed selling 8,442 shares of common stock, valued at over $90,000, around September 28, 2026. This follows a previous sale of 31,487 restricted stock units worth nearly $400,000 on August 19, 2026, under a 10b5-1 plan. The filings provide details on both transactions, including the acquisition nature and market values.
An officer plans to sell 9,020 Kura Oncology (KURA) shares
Kura Oncology officer Brian T. Powl intends to sell 9,020 common shares with an aggregate market value of $97,055.20, planned for September 28, 2026. These shares were acquired from the issuer through restricted stock units. The filing also details two previous restricted stock unit sales by Powl in the preceding three months, totaling approximately $136,160.87.
Form 144 KURA ONCOLOGY For: 28 September By Investing.com
This article is a Form 144 filing for KURA Oncology, dated September 28. It is a brief, standard financial disclosure without additional commentary. The article includes current stock market data and links to related financial news.
Shares valued at $49,571 are in a proposed sale by Kura Oncology (KURA) officer Thomas James Doyle.
Kura Oncology Officer Thomas James Doyle has proposed the sale of 4,607 shares of common stock, valued at an aggregate market value of $49,571.32. This proposed sale, occurring through a Rule 144 notice, is scheduled for approximately September 28, 2026. The shares were acquired as PSUs from the issuer on September 27, 2026, and Morgan Stanley Smith Barney LLC is named as the broker.
Kura Oncology CSO Francis Burrows Executes Stock Option and Sells Shares in September 2026
Kura Oncology's Chief Scientific Officer, Francis Burrows, executed a stock option for 30,000 shares at $6.15 each and subsequently sold 20,726 shares at a weighted average price of $10.8325 on September 24, 2026. These transactions were cashless and intended to cover payroll tax obligations. After these dealings, Burrows directly holds 42,327 shares of common stock.
After exercising options, Kura Oncology (KURA) science chief sold 20,726 shares to cover estimated payroll taxes.
Kura Oncology's Chief Scientific Officer, Burrows Francis, exercised 30,000 fully vested stock options at $6.15 per share on September 24, 2026. He then sold 20,726 of these shares at a weighted average price of $10.8325 to cover estimated payroll tax liabilities. Following these transactions, Francis holds 42,327 common shares and no remaining stock options.
Form 144 KURA ONCOLOGY For: 25 September By Investing.com
This article briefly reports on the filing of Form 144 for KURA Oncology on September 25, 2026. Form 144 filings indicate an intent to sell restricted securities, signaling potential insider trading or significant shareholder activity. The report provides no additional details beyond the filing date and company name.
Form 144 KURA ONCOLOGY For: 25 September By Investing.com
The article is a brief financial announcement from Investing.com, stating the filing of Form 144 for KURA Oncology. It specifies the date of the filing as September 25, implying a regulatory disclosure regarding the company's securities.
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514.
An officer of Kura Oncology (KURA), Francis John Burrows, has proposed selling 20,726 common shares with an aggregate market value of $224,514.40. These shares were acquired through a stock option exercise on September 24, 2026, and the proposed sale date is also September 24, 2026. Morgan Stanley Smith Barney LLC has been identified as the broker for this transaction.
Kura Oncology stock holds at USD 11.73 as Caspian launches
Kura Oncology's stock closed at USD 11.73, while its fair value is estimated at USD 31.17, indicating a significant valuation gap. This gap is attributed to the expected approval and commercial launch of ziftomenib and the development of Caspian Therapeutics, a venture backed by a USD 50 million raise. Caspian adds a second pipeline angle, broadening the potential use of Kura's menin-inhibitor platform beyond oncology.
Kura Oncology Q2 2026 Earnings Call Transcript
Kura Oncology reported strong Q2 2026 financial results, with Comzifti achieving $9.1 million in net product revenue and capturing a majority of new patient starts in the relapsed refractory NPM1 mutant AML menin inhibitor market. The company is advancing Comzifti as a foundational therapy in AML through combination studies and is developing Darla Farnab as a second strategic asset for solid tumors. Kura maintains a strong financial position, with $519 million in cash, expected to fund the ziftomenib AML program through 2028, and anticipates multiple clinical updates in late 2026.
Kura Oncology at Morgan Stanley conference: early sales, bigger bets
Kura Oncology presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its transition from a development-stage to a commercial-stage company. The company reported early sales success for its AML drug KOMZIFTI and outlined its broader pipeline, including frontline AML studies, a second oncology franchise, and a new metabolic-disease spinout called Caspian Therapeutics. Kura remains well-capitalized, with its current cash and anticipated milestones expected to fund AML programs through 2028.
Kura spins diabetes work into a Lilly-backed biotech startup
Kura Oncology has spun off a new biotech startup, Caspian Therapeutics, to develop menin inhibitors for diabetes and other cardiometabolic conditions. Caspian has secured $50 million in funding from investors including Eli Lilly and the T1D Fund, with Kura retaining a 50% stake. The startup will focus on KO-7246, a drug showing preclinical promise in regenerating pancreatic beta cells and increasing insulin production, representing a novel application for menin inhibitors previously approved for leukemia.
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology (NASDAQ: KURA) has announced a significant strategic pivot by launching Caspian Therapeutics, a new subsidiary focused on advancing its menin-inhibition strategy for chronic metabolic diseases. Caspian Therapeutics secured $50 million in financing and will develop KO-7246, a next-generation menin inhibitor for diabetes, with Kura Oncology retaining approximately half ownership. This move aims to expand development capacity and fund initial clinical proof-of-concept for its lead asset.
Kura Oncology at cantor conference: rapid launch, wider ambitions
Kura Oncology presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting the rapid commercial adoption of KOMZIFTI in acute leukemia and its broader pipeline ambitions, including solid tumors and diabetes. The company reported KOMZIFTI achieved a majority share of new patient starts in NPM1-mutated acute leukemia and outlined upcoming data releases and Phase III trial progress. Kura also announced the spin-out of Caspian Therapeutics to pursue menin inhibitors in diabetes, demonstrating a strategic focus on efficient capital allocation while expanding its therapeutic reach.
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology has launched Caspian Therapeutics with $50 million in financing to develop menin inhibitors for diabetes and cardiometabolic diseases. Caspian will advance KO-7246, a highly selective menin inhibitor, through preclinical and early clinical development, focusing on its potential to regenerate pancreatic β cells and restore insulin production. Kura Oncology retains a substantial ownership stake in Caspian while continuing to focus on its oncology pipeline.
Kura Oncology (KURA) awards CFO 450,000 stock options
Kura Oncology's CFO, Jennifer Fulk, received a grant of 450,000 stock options with an exercise price of $12.52 per share and an expiration date of September 7, 2036. This grant was made on September 8, 2026, under a Rule 10b5-1 trading plan. The options will vest over time, with one-fourth vesting on the one-year anniversary of the commencement date and the remainder in monthly installments thereafter.
Kura Oncology (KURA) CFO files initial ownership report with no trades
Kura Oncology's CFO, Jennifer Fulk, filed an initial Form 3 statement of beneficial ownership, indicating no current transactions or derivative holdings in KURA securities. This filing, marked as neutral in impact and sentiment, confirms that no shares were bought or sold, nor were any derivative positions like stock options reported. The document was accepted by the SEC on September 10, 2026.
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology has launched Caspian Therapeutics with a $50 million financing round to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian will focus on KO-7246, a menin inhibitor designed to stimulate pancreatic β-cell proliferation and increase insulin production, aiming to restore endogenous insulin-producing capacity. Kura Oncology will retain a substantial ownership stake in Caspian while continuing to focus on its oncology pipeline.
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology has announced the appointment of Jennifer Fulk as its new Chief Financial Officer, effective September 8, 2026. Ms. Fulk brings over 20 years of financial and operating leadership experience from the biopharmaceutical industry, including senior roles at Eli Lilly and as CFO of other public companies. Her appointment is expected to help Kura Oncology maximize the commercial potential of KOMZIFTI and advance its precision oncology pipeline.
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology, a biopharmaceutical company, has appointed Jennifer Fulk as its new Chief Financial Officer, effective September 8, 2026. Fulk brings over 20 years of experience in finance and operations within the biopharmaceutical sector and will play a key role as Kura Oncology moves into its next phase as a commercial-stage company. Her expertise will be crucial for maximizing the commercial potential of KOMZIFTI® and advancing other pipeline candidates.
Price-Driven Insight from (KURA) for Rule-Based Strategy
This article provides a price-driven insight for Kura Oncology Inc. (NASDAQ: KURA) for a rule-based strategy. It presents neutral near-term readings, strong mid-term sentiment, and offers specific institutional trading strategies including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis suggests compelling upside potential as no resistance levels remain above the current price.
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run
Kura Oncology's stock has seen a 55.5% return over the past year, but valuation checks suggest it is now expensive. The company's P/S ratio of 15.1x is above industry and peer averages, indicating it may be overvalued despite progress in its KOMZIFTI and darlifarnib programs. Investors are left to question if future execution can justify the current premium.
Kura Oncology to Participate in Three Investor Conferences in September
Kura Oncology, Inc., a biopharmaceutical company specializing in cancer treatments, announced its participation in three investor conferences in September 2026: the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. Management will present at these events, and live audio webcasts will be available on the company's website. Kura Oncology focuses on precision medicines, including its FDA-approved drug KOMZIFTI®, for various hematologic malignancies and solid tumors.
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade reflects an upward trend in earnings estimates for the biopharmaceutical company, which is a strong indicator for potential stock price appreciation. The Zacks Rank system, which correlates highly with near-term stock movements, suggests Kura Oncology could offer market-beating returns.
Kura Oncology to Participate in Three Investor Conferences in September
Kura Oncology, Inc., a biopharmaceutical company focused on cancer treatments, announced its participation in three investor conferences in September 2026. Management will present at the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. Live audio webcasts and archived replays will be available on the company's website.
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today
Kura Oncology (KURA) stock rallied significantly after CEO Troy Wilson made a substantial insider purchase of 100,000 shares for $1.24 million, adding to a previous $1.11 million investment. This insider buying signals confidence in the biotech firm, especially as its share price has already seen a strong increase. The company's stock performance is also supported by the commercial success of its FDA-approved treatment, KOMZIFTI, and expectations of future collaboration payments and positive trial results.
Kura Oncology Shares Rise After CEO Purchases 100,000 Shares
Kura Oncology's stock increased following its CEO's purchase of 100,000 shares. The company, a clinical-stage biopharmaceutical firm, focuses on precision medicine for cancer treatment with several small molecule product candidates in its pipeline. Analysts currently have a "BUY" consensus rating on Kura Oncology, with an average target price significantly above its last closing price.
Kura Oncology Shares Surge 9% Following CEO’s $2.35 Million Purchase Over Eight Days
Kura Oncology's shares surged by 8.87% after CEO Troy Wilson acquired 200,000 shares for $2.351 million over eight days, creating an unrealized profit of $349,000. This insider confidence is bolstered by strong growth in Kura's debut product, KOMZIFTI, which saw a 57% sequential increase in net product revenue. Despite a net loss, the company maintains a robust balance sheet with $519 million in cash, supporting its ziftomenib program.
Kura Oncology Shares Jump After CEO Buys $1.24 Million of Stock
Kura Oncology Inc. (NASDAQ:KURA) shares surged by 11.0% in pre-market trading after its President and CEO, Troy Edward Wilson, purchased 100,000 shares worth $1.24 million. This significant insider buying, executed at a weighted average price of $12.39 per share, increased Wilson's indirect ownership and is seen by investors as a strong signal of confidence in the biotechnology company's future prospects.
Kura Oncology CCO Brian Powl sells $51,663 in shares
Brian T. Powl, Chief Commercial Officer at Kura Oncology, Inc., sold 4,345 shares of the company's common stock for $51,663 on August 21, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, with InvestingPro analysis suggesting it is overvalued. Despite this, Kura Oncology recently exceeded Q2 2026 financial expectations and received a "Market Outperform" rating from Citizens, partly due to strong early sales of its new cancer drug, KOMZIFTI, and a significant insider stock purchase by the CEO.
Kura Oncology stock jumps after CEO buys $1.24M in shares
Kura Oncology Inc. (NASDAQ:KURA) shares rose 11.0% in premarket trading after President and CEO Troy Edward Wilson purchased $1.24 million worth of company stock. Wilson acquired 100,000 shares at a weighted average price of $12.39, significantly increasing his indirect and direct holdings. This insider purchase is often seen as a signal of management's confidence in the company's future prospects.
Kura Oncology (KURA) Shares Rise 8.7% Following Insider Purchase; P/S Valuation Signals Growth Expectations
Kura Oncology (KURA) shares rose 8.7% after President and CEO Troy Wilson purchased 100,000 shares, signaling executive confidence. The company's Price-to-Sales ratio of 14.18 is high, reflecting market expectations for strong future revenue growth despite current unprofitability. KURA's GF Score of 28/100 indicates weak fundamentals, with high momentum but low profitability and financial health, positioning it as a high-risk, high-reward speculative growth stock.
Kura Oncology (KURA) Chief Commercial Officer Brian Powl Sells 4,345 Shares
Kura Oncology's Chief Commercial Officer, Brian Powl, sold 4,345 shares of the company on August 21, 2026, for approximately $51,662. This transaction is part of a larger trend of insider selling at the company, with 26 insider sells against 3 insider buys over the past year, though Powl still holds a significant stake. Despite insider selling, GuruFocus's data indicates that more institutional investors (gurus) are adding to their positions than trimming, suggesting a divergence in sentiment between insiders and some institutional investors regarding Kura Oncology's long-term potential in developing precision cancer medicines.
Kura Oncology (NASDAQ: KURA) CEO buys 100K shares in open-market trade
Kura Oncology's President and CEO, Troy Edward Wilson, through the One Fish Two Fish Revocable Trust, purchased 100,000 shares of common stock on August 24, 2026, at a weighted average price of $12.39 per share. This transaction involved individual trades ranging from $11.47 to $12.85. Following this purchase, the trust indirectly holds 479,194 shares, in addition to other indirect and direct holdings by Wilson.
Kura Oncology (KURA) CCO sells 4,345 shares in plan trade
Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 4,345 shares of common stock on August 21, 2026, at a weighted average price of $11.8903 per share. This transaction was executed as a pre-arranged 10b5-1 trading plan adopted on December 18, 2025. Following the sale, Powl directly holds 169,269 shares of Kura Oncology common stock.
KURA Reiterates by Citizens -- Rating Maintained at Market Outpe
Citizens analyst Reni J. Benjamin has reiterated a Market Outperform rating for Kura Oncology (KURA), maintaining a price target of $24.00, which suggests significant upside from its current trading price. Despite this positive analyst sentiment and strong stock momentum, KURA's GF Score™ of 28/100, high price-to-sales ratio, and unprofitability indicate potential overvaluation, warranting caution from investors. Insider activity also shows mixed signals with more sales than buys recently.
